BWAY delivered a clean Q1 earnings beat on Tuesday, yet the stock ended the session slightly lower. That disconnect — good numbers, tepid price reaction — is the clearest tension heading into the rest of the week.
Q1 EPS came in at $0.06, topping the $0.05 consensus. Revenue of $15.5 million beat the $14.5 million estimate by roughly 7%. Management also affirmed full-year 2026 sales guidance of $66 million–$68 million, bracketing the Street's $66.4 million estimate almost precisely. On paper it's a well-executed quarter. Yet multiple outlets noted shares slipped over 2% on the session. The market's reaction tells its own story: investors either wanted a guidance raise or are simply taking profits after a strong run — BWAY is up 12% over the past month.
The lending market shows no conviction from short sellers either way. Short interest is near zero — just 0.015% of the free float, roughly unchanged on the week and well below the 0.017% level briefly seen in early April. With borrow availability running at roughly 968% of short interest, there is no material short positioning to speak of and no squeeze dynamic in play. What makes the borrow picture more interesting is the cost: at 14.1% annualised, the cost to borrow has climbed about 18% over the past month after holding flat for much of the year prior. It jumped from the ~11.8% range in late January, suggesting a modest increase in demand for borrows even as the actual short float remains negligible. The ORTEX short score of 35.2 is creeping higher week-on-week — from 33.7 on May 6 to 35.2 on May 12 — though at this level it is not signalling anything alarming.
The real story at BrainsWay remains operational. The Q4 2025 earnings call revealed 10 consecutive quarters of profitability, a book-to-bill ratio of 1.4x, and a remaining performance obligation that grew 43% year-over-year to $70 million. The company's pivot to enterprise leasing contracts has converted what was once a lumpy capital equipment business into a recurring revenue model with meaningful forward visibility. Management estimates penetration below 10% of addressable market — a claim that is hard to verify independently but consistent with revenue still growing at a 27% clip. Q1 shows the pace is holding: revenue was up sequentially from Q4's $14.5 million print.
Institutional ownership reflects the small-cap reality of a company that trades in Tel Aviv but attracts US-based money. Valor Management holds 13.3% — by far the largest institutional stake — and added over 1.1 million shares at the most recent reporting date. Meitav Investment House added nearly 1 million shares in Q1, bringing its position to 3.1% of the company. On the other side, David Zacut trimmed by 375,000 shares as of March, while Abraham Zangen and Yiftach Roth made smaller reductions. The insider data in the snapshot is entirely stale — dating back to 2018-2019 — and should be disregarded as a signal of current intent.
For context, BWAY's closest correlated peer on TASE, SOFW, fell 5.5% on the week and dropped nearly 3% on Tuesday alone. That divergence mattered: BWAY actually closed Tuesday up 1.2% and gained 1.9% over the five sessions, outperforming its most direct local comparison by roughly 7 percentage points. ISRG — the largest peer by market cap in the basket — also slipped 4.3% on the week, though on entirely different fundamentals.
The next scheduled event is a follow-up earnings call for Q1 on May 14. With results already out and guidance reaffirmed, that call is now less about the numbers and more about management's commentary on payer coverage expansion, the accelerated SWIFT protocol adoption timeline, and any update on the NIH-funded alcohol use disorder trial — the clinical catalysts the market will use to calibrate whether the current valuation multiple is justified.
See the live data behind this article on ORTEX.
Open BWAY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
